Claims for Patent: 7,449,181
✉ Email this page to a colleague
Summary for Patent: 7,449,181
Title: | Remedies for cancer |
Abstract: | A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient. |
Inventor(s): | Noguchi; Toshihiro (Ibaraki, JP), Baba; Akemi (Oklahoma City, OK), Hanada; Mitsuharu (Ibaraki, JP) |
Assignee: | Sumitomo Pharmaceuticals Company Limited (Osaka-Shi, JP) |
Application Number: | 10/333,978 |
Patent Claims: | 1. A method of treating breast cancer, which is a breast cancer in which HER2 is highly expressed, comprising administering an effective amount of trastuzumab and an
effective amount of amrubicin or a pharmaceutically acceptable salt thereof in combination, whereby said breast cancer is treated.
2. The method according to claim 1, comprising administering amrubicin or a pharmaceutically acceptable salt thereof at 0.5 3.0 mg/kg/day while administering trastuzumab at 0.1 4.5 mg/kg/day. 3. The method according to claim 2, comprising administering amrubicin or a pharmaceutically acceptable salt thereof on successive three days in every three weeks, while administering trastuzumab every one week. 4. The method according to claim 1, comprising administering amrubicin or a pharmaceutically acceptable salt thereof at 1.5 9.0 mg/kg/day while administering trastuzumab at 0.1 4.5 mg/kg/day. 5. The method according to claim 4, comprising administering amrubicin or a pharmaceutically acceptable salt thereof every three weeks, while administering trastuzumab every one week. 6. The method according to any one of claims 1 and 2 to 5, wherein a dosage ratio of amrubicin or a pharmaceutically acceptable salt thereof and trastuzumab is 2:1 8:1 at one week after initiating the administration of both agents. |
Details for Patent 7,449,181
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2020-07-28 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2020-07-28 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2020-07-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.